Natera Files Patent Infringement Suit Against NeoGenomics
31 Julho 2023 - 2:39PM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
testing, today announced that it has filed a lawsuit in the North
Carolina Federal District Court against NeoGenomics Labs, Inc.
("NeoGenomics") for infringement of Natera's U.S. Patent Nos.
11,519,035 and 11,530,454 by NeoGenomics’ RaDaR molecular residual
disease assay.
This lawsuit builds on Natera's current patent infringement
lawsuit in the United States District Court for the District of
Delaware related to RaDaR tests sold by Inivata, an affiliate of
NeoGenomics. The company's filing of this new suit follows a recent
jury verdict in favor of Natera in the U.S. District Court for the
District of Delaware in the patent infringement suit it filed
against ArcherDX/Invitae Corp.
About Signatera
Signatera™ is a custom-built circulating tumor DNA (ctDNA) test
for treatment monitoring and molecular residual disease (MRD)
assessment in patients previously diagnosed with cancer. The test
is available for both clinical and research use, and has been
granted three Breakthrough Device Designations by the FDA for
multiple cancer types and indications. The Signatera test is
personalized and tumor-informed, providing each individual with a
customized blood test tailored to fit the unique signature of
clonal mutations found in that individual’s tumor. Signatera is
intended to detect and quantify cancer left in the body, at levels
down to a single tumor molecule in a tube of blood, to identify
recurrence earlier and to help optimize treatment decisions.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and inform earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 150 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to
developments in matters under dispute or litigation, the scope of
protection we establish and maintain for, and developments or
disputes concerning, our intellectual property or other proprietary
rights, and our expectations of the benefits of our tests and
product offerings to patients, providers and payers. Additional
risks and uncertainties are discussed in greater detail in “Risk
Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230731657407/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024